Ticker
GYRECompany Name
GYRE THERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQDate | Market Capitalization | Net Cash Flow - Issuance (Purchase) of Equity Shares | Net Cash Flow - Issuance (Repayment) of Debt Securities | Net Cash Flow - Dividends & Other Cash Distributions | Shareholder Yield |
---|---|---|---|---|---|
6/30/2025 | $ 679.01M | $ 27.2M | $ 0 | $ 0 | -4.01% |
3/31/2025 | $ 893.51M | $ 3.44M | $ 0 | $ 0 | -0.39% |
12/31/2024 | $ 1.15B | $ 2.64M | $ 0 | $ 0 | -0.23% |
9/30/2024 | $ 1.35B | $ 1.28M | $ 0 | $ 12.76M | -1.04% |
6/30/2024 | $ 971.61M | $ 931K | $ 0 | $ 11.26M | -1.26% |
3/31/2024 | $ 1.35B | $ 656K | $ 0 | $ 7.76M | -0.63% |
12/31/2023 | $ 1.5B | $ 0 | $ 0 | $ 0 | 0% |
9/30/2023 | $ 20.47M | $ 24K | $ 0 | $ -12.76M | 62.24% |
6/30/2023 | $ 13.26M | $ 6K | $ 0 | $ -56.3M | 424.56% |
3/31/2023 | $ 8.31M | $ 6K | $ 0 | $ -52.8M | 635.46% |
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
(-1 * CF - Equity -1 * CF - Dividends -1 * CF - Debt) / Market Cap
(=) Shareholder Yield
Shareholder Yield for GYRE THERAPEUTICS INC is calculated as follows: (-1 * CF - Equity [ $ 60.38M ] -1 * CF - Dividends [ $ 0 ] -1 * CF - Debt [ $ 0 ]) / Market Cap [ $ 128.39M ]
(=) Shareholder Yield [ -47.03% ]
Minimum
Dec 31, 2021
Maximum
Mar 31, 2023
Average
Median
filtered constituents | 3.48K |
---|---|
min | -33.43% |
max | 34.45% |
average | 0.57% |
median | 1.07% |
std | 11.13% |